Blincyto Kit
Product Images NDC 55513-160

31 FDA label images from Amgen, Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 31 technical images submitted to the FDA as part of the official labeling for Blincyto (NDC 55513-160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Blincyto 01)

Figure 1 (Blincyto 01)
A Kaplan-Meier survival curve graph comparing overall survival probability over 27 months for Blincyto (blinatumomab) and standard-of-care chemotherapy (SOC Chemo) groups. The graph includes median overall survival (OS) times, hazard ratio (HR) with confidence intervals, p-value, and the number of subjects at risk over time, with censoring indicated by vertical bars.*
FDA Label Image

Figure 2 (Blincyto 02)

Figure 2 (Blincyto 02)
Label of BLINCYTO (blinatumomab) for Injection, 35 mcg per vial, manufactured by Amgen, Inc. It is a single-dose vial intended for intravenous infusion only. The label includes storage instructions (2°C to 8°C) and a note that the vial contains no preservative. The label emphasizes not to shake the reconstituted solution and mentions dispensing the enclosed medication guide.*
FDA Label Image

Figure 3 (Blincyto 03)

Figure 3 (Blincyto 03)
A Kaplan-Meier survival probability graph comparing BLINCYTO (blinatumomab) treatment versus chemotherapy over 84 months. The chart shows survival probability on the vertical axis and months on the horizontal axis, with survival curves for chemotherapy (N=57) and BLINCYTO (N=54). The 5-year survival estimates with 95% confidence intervals are 41.4% (26.3, 55.9) for chemotherapy and 78.4% (64.2, 87.4) for BLINCYTO, with a hazard ratio of 0.35 (95% CI: 0.17, 0.70) from stratified Cox regression.*
FDA Label Image

Figure 4 (Blincyto 04)

Figure 4 (Blincyto 04)
A Kaplan-Meier survival curve showing survival probability over months for two treatments: chemotherapy and Blincyto. The solid line represents chemotherapy with a 5-year survival estimate of 27.6%, and the dotted line represents Blincyto with a 5-year survival estimate of 61.1%. Number of subjects at risk is listed below the x-axis, which is labeled in months, and survival probability is on the y-axis. A hazard ratio with 95% confidence interval from Cox regression is noted at the top right.*
FDA Label Image

Image (Blincyto 05)

Image (Blincyto 05)
The image shows a vial labeled with "sWFI" representing sterile water for injection, often used for dilution or reconstitution of injectable drugs. The vial has a capped neck. This is related to BLINCYTO (blinatumomab) KIT by Amgen, Inc.*
FDA Label Image

Image (Blincyto 06)

FDA Label Image

Image (Blincyto 07)

Image (Blincyto 07)
The image shows a vial likely representing BLINCYTO (blinatumomab) kit. It is a simple black and white line drawing of a medicine vial with a label area and a cap. The vial is shown upright with no detailed text visible on the label.*
FDA Label Image

Image (Blincyto 08)

Image (Blincyto 08)
BLINCYTO (blinatumomab) kit packaging label from Amgen, Inc. The label features the proprietary name BLINCYTO prominently. The product is a human prescription drug provided in kit form. The label includes the NDC number 55513-160 and shows manufacturer details for Amgen, Inc.*
FDA Label Image

Image (Blincyto 09)

Image (Blincyto 09)
Image of a vial presumably representing BLINCYTO (blinatumomab) kit from Amgen, Inc. The vial is shown with a cap and label area, but no legible text or additional details are visible on the label in the image.*
FDA Label Image

Image (Blincyto 10)

Image (Blincyto 10)
BLINCYTO kit by Amgen, Inc, containing blinatumomab. The front label of the cardboard carton is shown, including the product name BLINCYTO prominently displayed, the generic name blinatumomab in smaller text, and usage as a prescription drug. The packaging is primarily white with blue and grey accents.*
FDA Label Image

Image (Blincyto 11)

Image (Blincyto 11)
Packaging label image showing three glass vials containing Normal Saline solution. The vials have gray caps and white labels with the text 'Normal Saline' visible on the front vial. No specific product brand or dosage details are provided in the image.*
FDA Label Image

Image (Blincyto 12)

FDA Label Image

Image (Blincyto 13)

Image (Blincyto 13)
An illustration showing a medical fluid bag with two ports on top, typically used for intravenous infusion. The bag features an empty label area on the front and a rounded bottom with a triangular drainage point.*
FDA Label Image

Image (Blincyto 14)

Image (Blincyto 14)
An illustration showing a vial with a cap next to a plus sign, indicating a combination or mixing process. The vial is labeled with a rectangular blank area, suggesting medication or drug preparation.*
FDA Label Image

Image (Blincyto 15)

Image (Blincyto 15)
An illustration showing a vial and a syringe combined with a plus sign, symbolizing the preparation or mixing of a drug product, likely referencing the BLINCYTO kit for administration.*
FDA Label Image

Image (Blincyto 16)

Image (Blincyto 16)
An instructional illustration showing the top portion of an IV bag with two ports and an instruction pointing to the liquid level stating, "Remove air from the IV Bag." The drawing highlights safe preparation steps for intravenous administration.*
FDA Label Image

Image (Blincyto 17)

Image (Blincyto 17)
An instructional illustration showing a medical infusion bag connected to tubing labeled to prime with the final prepared BLINCYTO (blinatumomab) solution. The image depicts part of the preparation or administration process for this prescription drug kit by Amgen, Inc.*
FDA Label Image

Image (Blincyto 18)

Image (Blincyto 18)
Image of a vial labeled with 'sWFI,' representing sterile water for injection (WFI). The vial has a narrow neck and a cap on top. No additional labeling or branding visible.*
FDA Label Image

Image (Blincyto 19)

FDA Label Image

Image (Blincyto 20)

Image (Blincyto 20)
BLINCYTO (blinatumomab) kit vial with a stopper and sealed cap. The vial is clear, showing a light gray circular label or marking on the front, with no additional text or details visible. The image depicts the dosage form as a vial, labeled with the brand and generic names and the labeler Amgen, Inc.*
FDA Label Image

Image (Blincyto 21)

Image (Blincyto 21)
BLINCYTO kit packaging label showing the proprietary name BLINCYTO and the generic name blinatumomab. The label includes the Amgen, Inc. labeler name and product NDC 55513-160. The image shows a carton or box design typically used for the kit dosage form of this human prescription drug.*
FDA Label Image

Image (Blincyto 22)

Image (Blincyto 22)
BLINCYTO (blinatumomab) kit vial image showing a small medicine bottle with a cap and a round label area on the front. The label details are not readable; the vial is portrayed in a simple line drawing style. Manufactured by Amgen, Inc.*
FDA Label Image

Image (Blincyto 23)

Image (Blincyto 23)
BLINCYTO (blinatumomab) kit image showing three small glass vials with black caps and black labels. The front vial label reads 'B.static Saline' in white text. The labeler is Amgen, Inc. and the dosage form is a kit.*
FDA Label Image

Image (Blincyto 24)

FDA Label Image

Image (Blincyto 25)

Image (Blincyto 25)
BLINCYTO blinatumomab human prescription drug kit by Amgen, Inc. The image shows a medical infusion bag with two ports on top and a flat bottom, commonly used for intravenous administration of the medication.*
FDA Label Image

Image (Blincyto 26)

Image (Blincyto 26)
An illustration showing two components: a vial with a gray cap on the left and a larger bottle with a gray label on the right, separated by a plus sign, suggesting a combination or mixture of these items.*
FDA Label Image

Image (Blincyto 27)

Image (Blincyto 27)
Illustration depicting two components of a medication kit, featuring a vial with a cap and a cylindrical container or syringe, separated by a plus sign. The image suggests combination or preparation of two kit parts but does not show text or specific details beyond the visuals.*
FDA Label Image

Image (Blincyto 28)

Image (Blincyto 28)
An illustration showing a vial labeled "Normal Saline" and a plus sign next to it, indicating the combination or mixing of the vial contents with another substance. There is no additional product labeling visible.*
FDA Label Image

Image (Blincyto 29)

Image (Blincyto 29)
An instructional diagram showing the top portion of an IV bag with two ports. The diagram includes an arrow pointing to the bag with text that reads 'Remove air from the IV Bag.' This illustration demonstrates the step of removing air from the IV bag before use.*
FDA Label Image

Image (Blincyto 30)

Image (Blincyto 30)
An instructional illustration showing a fluid bag with tubing labeled 'Prime with FINAL prepared BLINCYTO solution.' The image demonstrates priming the infusion line with BLINCYTO (blinatumomab) solution before administration, relevant for the BLINCYTO kit by Amgen, Inc.*
FDA Label Image

Principal Display Panel (Kit Package)

Principal Display Panel (Kit Package)
BLINCYTO (blinatumomab) for Injection kit label showing a 35 mcg/vial strength. The label indicates this is a single-dose vial with no preservative, intended for intravenous infusion only. The product is manufactured by Amgen, Inc and includes instructions to store refrigerated at 2°C to 8°C and to protect from light.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.